#CorestemChemon
LightNews LightNews
newsen.bsky.social
CorestemChemon's Neuronata-R Advances toward ALS Stem Cell Market in Korea and the U.S.#South_Korea#Seoul#Neuronata-R#CorestemChemon#ALS_Therapies
CorestemChemon's Neuronata-R Advances toward ALS Stem Cell Market in Korea and the U.S.
CorestemChemon is making significant strides in ALS stem cell therapy with Neuronata-R, focusing on regulatory processes in Korea and expanding into the U.S. market.
third-news.com
December 18, 2025 at 2:48 AM
newsen.bsky.social
Neuronata-R Receives Extended Approval in South Korea for ALS Patients with New Clinical Insights#South_Korea#Seoul#ALS#Neuronata-R#CorestemChemon
Neuronata-R Receives Extended Approval in South Korea for ALS Patients with New Clinical Insights
The Ministry of Food and Drug Safety in South Korea has granted continued approval for Neuronata-R, a cell therapy for ALS, based on new clinical trial results, enhancing patient access.
third-news.com
July 19, 2026 at 11:05 PM
newsen.bsky.social
Neuronata-R® Phase 3 Trial Delivers Positive Results, Pushing Towards FDA Approval Pathway#South_Korea#Seoul#ALS#Neuronata-R#CorestemChemon
Neuronata-R® Phase 3 Trial Delivers Positive Results, Pushing Towards FDA Approval Pathway
CorestemChemon's Neuronata-R® shows potential in ALS treatment, highlighting significant improvements in specific patient subgroups at PACTALS 2025.
third-news.com
September 18, 2025 at 2:51 AM
alsadvocacy.bsky.social
"...by the end of 2025..."
ALS clock?
www.bioworld.com/articles/721...
Corestemchemon preps US BLA filing for stem cell ALS therapy
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company officials confirmed to BioWorld during a June ...
www.bioworld.com
June 11, 2025 at 10:25 AM
newsen.bsky.social
CorestemChemon Collaborates with ATG Lifetech to Enhance Preclinical Research Services#South_Korea#Seoul#preclinical_CRO#CorestemChemon#ATG_Lifetech
CorestemChemon Collaborates with ATG Lifetech to Enhance Preclinical Research Services
CorestemChemon announces a partnership with ATG Lifetech, aiming to innovate preclinical solutions for drug discovery through advanced technologies.
third-news.com
July 21, 2025 at 3:00 AM
labnews.bsky.social
Neuronata-R®-Phase-3-Ergebnisse bestätigen Nutzen in ALS-Untergruppe

Das südkoreanische Biotechnologieunternehmen CorestemChemon Inc. (KOSDAQ: 166480) hat auf dem PACTALS 2025-Kongress in Melbourne, Australien, Ergebnisse der Phase-3-Studie ALSUMMIT zu seiner Stammzelltherapie Neuronata-R®…
Neuronata-R®-Phase-3-Ergebnisse bestätigen Nutzen in ALS-Untergruppe
Das südkoreanische Biotechnologieunternehmen CorestemChemon Inc. (KOSDAQ: 166480) hat auf dem PACTALS 2025-Kongress in Melbourne, Australien, Ergebnisse der Phase-3-Studie ALSUMMIT zu seiner Stammzelltherapie Neuronata-R® (Lenzumestrocel) für amyotrophe Lateralsklerose (ALS) präsentiert. Obwohl die Studie die primären und sekundären Endpunkte insgesamt nicht erreichte, zeigten Patienten mit langsameren Krankheitsverläufen signifikante Verbesserungen in der Funktionserhaltung und Atmungskapazität. In der Untergruppe der Slow-Progressor-Patienten führte Neuronata-R®, eine autologe Therapie mit mesenchymalen Stammzellen (MSC) aus dem Knochenmark, nach 12 Monaten zu einer ALSFRS-R-Skala von 31,2 Punkten gegenüber 26,4 im Placebo (p=0,001).
lab-news.de
September 18, 2025 at 8:27 AM
l2plabs.bsky.social
CorestemChemon Advances Toward ALS Stem Cell Commercialization with Regulatory Progress in Korea and NSF-Backed U.S. Expansion
SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an...
dlvr.it
December 18, 2025 at 2:34 AM
l2plabs.bsky.social
Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway
Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key...
dlvr.it
September 18, 2025 at 2:30 AM
l2plabs.bsky.social
CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services
Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery SEOUL, South Korea, July 20, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical CRO based in South Korea, has entered into a strategic...
dlvr.it
July 21, 2025 at 2:59 AM
drtimos.bsky.social
Thoughts on this? >> CorestemChemon Expands Global CRO Reach with ATG Lifetech,
Targeting Next-Gen Preclinical Services >> Comment below! #mhealth #IoT #AI #industry40 #healthtech
CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services
Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery  SEOUL, South Korea, July 20, 2025 /PRNewswire/ — CorestemChemon, a leading GLP-certified preclinical CRO based in South Korea, has entered into a strategic partnership with ATG Lifetech, a biotechnology company specializing in transcriptome analytics and organoid-based modeling. This collaboration aims to deliver next-generation, …
dlvr.it
July 21, 2025 at 4:59 AM